Calton & Associates Inc. Sells 2,676 Shares of Merck & Co., Inc. (NYSE:MRK)

Calton & Associates Inc. trimmed its position in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 31.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,778 shares of the company’s stock after selling 2,676 shares during the period. Calton & Associates Inc.’s holdings in Merck & Co., Inc. were worth $474,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in MRK. Norges Bank bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth $1,823,028,000. BlackRock Inc. boosted its holdings in shares of Merck & Co., Inc. by 5.5% in the fourth quarter. BlackRock Inc. now owns 198,224,263 shares of the company’s stock worth $15,191,909,000 after acquiring an additional 10,326,974 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Merck & Co., Inc. by 12.7% in the fourth quarter. Geode Capital Management LLC now owns 48,153,283 shares of the company’s stock worth $3,682,009,000 after acquiring an additional 5,409,154 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of Merck & Co., Inc. by 13.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 28,981,674 shares of the company’s stock worth $2,221,156,000 after acquiring an additional 3,484,786 shares during the period. Finally, State Street Corp boosted its holdings in shares of Merck & Co., Inc. by 2.7% in the fourth quarter. State Street Corp now owns 118,668,673 shares of the company’s stock worth $9,174,491,000 after acquiring an additional 3,132,078 shares during the period. 72.88% of the stock is owned by institutional investors and hedge funds.

NYSE MRK opened at $89.16 on Thursday. The stock’s 50-day simple moving average is $88.75 and its two-hundred day simple moving average is $82.17. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $94.92. The company has a quick ratio of 1.14, a current ratio of 1.40 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $225.47 billion, a price-to-earnings ratio of 15.95, a PEG ratio of 1.19 and a beta of 0.36.

Merck & Co., Inc. (NYSE:MRKGet Rating) last released its quarterly earnings results on Thursday, April 28th. The company reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.81 by $0.33. Merck & Co., Inc. had a return on equity of 47.86% and a net margin of 26.27%. The business had revenue of $15.90 billion for the quarter, compared to the consensus estimate of $14.64 billion. During the same quarter last year, the business posted $1.40 earnings per share. The company’s revenue for the quarter was up 31.6% on a year-over-year basis. On average, equities analysts expect that Merck & Co., Inc. will post 7.32 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 8th. Shareholders of record on Wednesday, June 15th will be given a dividend of $0.69 per share. The ex-dividend date of this dividend is Tuesday, June 14th. This represents a $2.76 dividend on an annualized basis and a yield of 3.10%. Merck & Co., Inc.’s payout ratio is 49.37%.

A number of equities analysts have recently commented on MRK shares. Morgan Stanley cut their price target on Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. Barclays raised their price target on Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a report on Tuesday, April 12th. StockNews.com began coverage on Merck & Co., Inc. in a research report on Thursday, March 31st. They issued a “strong-buy” rating on the stock. SVB Leerink reiterated an “outperform” rating and issued a $102.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, June 6th. Finally, Mizuho began coverage on Merck & Co., Inc. in a research report on Friday, April 1st. They issued a “buy” rating and a $100.00 price objective on the stock. Seven research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $91.60.

Merck & Co., Inc. Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Recommended Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.